The Allstate Corporation (NYSE:ALL ) Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants Brent Vandermause - Head of IR Tom Wilson - President and CEO Jess Merten - EVP and CFO Mario Rizzo - President, Property-Liability Conference Call Participants Gregory Peters - Raymond James Jimmy Bhullar - JPMorgan Bob Huang - Morgan Stanley Jack Matten - BMO Yaron Kinar - Jefferies David Motemaden - Evercore ISI Charles Lederer - Citi Operator Good day, and thank you for standing by. Welcome to Allstate's Second Quarter Earnings Investor Call.

Allstate (ALL) witnesses lower property and casualty insurance claims and claims expenses in the second quarter.

While the top- and bottom-line numbers for Allstate (ALL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Allstate (ALL) came out with quarterly earnings of $1.61 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to loss of $4.42 per share a year ago.

NORTHBROOK, Ill.--(BUSINESS WIRE)--The Allstate Corporation (NYSE: ALL) today reported financial results for the second quarter of 2024. The Allstate Corporation Consolidated Highlights   Three months ended June 30,   Six months ended June 30, ($ in millions, except per share data and ratios) 2024   2023   % / pts Change     2024     2023   % / pts Change Consolidated revenues $ 15,714 $ 13,979   12.4 %   $ 30,973   $ 27,765   11.6 % Net income (loss) applicable to common shareholders   301   (.

Allstate's (ALL) second-quarter results are likely to reflect growing net investment income.

Improving business environment, underwriting practices and other factors are expected to have benefited insurance players in the second quarter. MET, AFL, AIG, ALL and EG will release earnings on Jul 31.

Better pricing, exposure growth, accelerated digitalization and sturdy capital are expected to help ACGL, ALL, PRU and RGA outperform second-quarter earnings estimates.

Today, we will discuss three recent analyst upgrades on Wall Street. Earnings season is in full swing, and the market is navigating volatility and uncertainty.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Allstate (ALL) have what it takes?

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Allstate (ALL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to UCART22 product candidate for the treatment of Acute Lymphoblastic Leukemia (ALL).